|
Mechanism5-HT2B receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Dec 2005 |
|
|
|
|
Active Indication- |
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz
Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.
[Translation] Human Bioequivalence Test of Telmisartan and Hydrochlorothiazide Tablets after Meal
选择 Boehringer Ingelheim Pharma GmbH &Co.生产的替米沙坦氢氯噻嗪片(商品名:Micardis Plus 美嘉素,规格:每片含替米沙坦 80mg.氢氯噻嗪 12.5mg)作为参比制剂,对韩国 DASAN 制药有限公司研制的替米沙坦氢氯噻嗪片进行餐后给药条件下人体生物等效性试验,用于评价其与参比制剂的人体生物等效性。
[Translation] Telmisartan and hydrochlorothiazide tablets produced by Boehringer Ingelheim Pharma GmbH & Co. (trade name: Micardis Plus, specification: each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide) were selected as the reference preparation. The developed telmisartan and hydrochlorothiazide tablets were subjected to a human bioequivalence test under the condition of postprandial administration to evaluate the human bioequivalence between it and the reference preparation.
[Translation] Fasting Human Bioequivalence Study of Telmisartan and Hydrochlorothiazide Tablets
选择 Boehringer Ingelheim Pharma GmbH &Co.生产的替米沙坦氢氯噻嗪片(商品名:Micardis Plus 美嘉素,规格:每片含替米沙坦 80mg.氢氯噻嗪 12.5mg)作为参比制剂,对韩国 DASAN 制药有限公司研制的替米沙坦氢氯噻嗪片进行空腹给药条件下人体生物等效性试验,用于评价其与参比制剂的人体生物等效性。
[Translation] Telmisartan and hydrochlorothiazide tablets produced by Boehringer Ingelheim Pharma GmbH & Co. (trade name: Micardis Plus, specification: each tablet contains 80 mg of telmisartan and 12.5 mg of hydrochlorothiazide) were selected as the reference preparation. The developed telmisartan and hydrochlorothiazide tablets were subjected to a human bioequivalence test under fasting conditions to evaluate their bioequivalence with the reference preparation.
100 Clinical Results associated with Pharma King Co., Ltd.
0 Patents (Medical) associated with Pharma King Co., Ltd.
100 Deals associated with Pharma King Co., Ltd.
100 Translational Medicine associated with Pharma King Co., Ltd.